Understanding the Pathophysiology of Cerebral Amyloid Angiopathy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Cerebral amyloid angiopathy (CAA), one of the main types of cerebral small vessel disease, is a major cause of spontaneous intracerebral haemorrhage and an important contributor to cognitive decline in elderly patients. Despite the number of experimental in vitro studies and animal models, the pathophysiology of CAA is still largely unknown. Although several pathogenic mechanisms including an unbalance between production and clearance of amyloid beta (Aβ) protein as well as ‘the prion hypothesis’ have been invoked as possible disease triggers, they do not explain completely the disease pathogenesis. This incomplete disease knowledge limits the implementation of treatments able to prevent or halt the clinical progression. The continuous increase of CAA patients makes imperative the development of suitable experimental in vitro or animal models to identify disease biomarkers and new pharmacological treatments that could be administered in the early disease stages to prevent irreversible changes and disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
Iadecola, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.030 · Cited by 2,480
Capillary pericytes regulate cerebral blood flow in health and disease
Hall, C. N., Reynell, C., Gesslein, B., Hamilton, N. B., Mishra, A., Sutherland, B. A., O’Farrell, F. M., Buchan, A. M., Lauritzen, M., & Attwell, D. (2014) · Nature · doi:10.1038/nature13165 · Cited by 1,870 · cited 1×
“The CBF has been demonstrated to be initially regulated by the dilation of pericytes in vivo, both under ischemic and healthy conditions, and a recent in vitro study pointing out the toxic effects of Aβ40 on this cellular population opened the way to questions on their implication in the CAA pathogenesis [13,14].”
BackgroundAlzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 3×
“It is also well-known that Aβ accumulation in the cerebral vessels interferes with the BBB ability to clear Aβ from the CNS [130].”
BackgroundApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 1×
“Indeed, pericytes have already been shown to respond to the astrocytic release of apoE by stopping the production of MMP-9, which would lead to BBB disruption if unregulated [15].”
BackgroundExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971
Prion-like transmission of protein aggregates in neurodegenerative diseases
Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2873 · Cited by 778
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · cited 1×
“Several works have studied the BBB properties to develop valuable tools to elucidate the mechanistic aspects of Aβ transport in the physio-pathological process, thus more likely predicting the in vivo context [64].”
BackgroundPathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 1×
“, by using soluble RAGE or anti-RAGE antibodies) suppress the accumulation of Aβ in brain parenchyma and reduces cerebrovascular vasoconstriction and neurovascular stress in transgenic mouse models [131,132].”
MethodRAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519 · cited 7×
“Abbreviations CAA Cerebral amyloid angiopathy CNS Central nervous system ICH Intracerebral haemorrhage Aβ Amyloid beta protein APP Amyloid precursor protein TFNEs Transient focal neurological events AD Alzheimer’s disease DW-MRI Diffusion weighted magnetic resonance imaging PET Positron emission tomography CSF Cerebro…”
BackgroundInfluentialEvidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., Launchbury, F., Linehan, J., Richard-Loendt, A., Walker, A. S., et al. (2015) · Nature · doi:10.1038/nature15369 · Cited by 518 · cited 1×
“Our report is in line with previous studies describing patients with early-onset iatrogenic CAA [37,38].”
ResultApolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412
Calhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K.-H., Abramowski, D., Sturchler-Pierrat, C., Sommer, B., Staufenbiel, M., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14088 · Cited by 410 · cited 7×
“Since rodents generally do not develop CAA spontaneously, not even at very old ages, a variety of transgenic mouse models have been introduced that, similar to cerebral amyloidosis in humans, develop either Aβ-CAA only or both Aβ-CAA and parenchymal amyloid, or primarily parenchymal amyloid.”
MethodInfluentialHerzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 3×
“The APPDutch mice were primarily designed to study CAA and are the only murine model that develops significant Aβ-CAA with no parenchymal amyloid plaques [49].”
BackgroundDavis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · cited 1×
“This transgenic mouse model was primarily designed to study CAA, through the overexpression of human APP770 containing the Swedish double mutation (K670N/M671L) and the Dutch and Iowa (D694N) mutations under the control of neuron-specific murine Thy-1 promoter element [105].”
MethodCarrano, A., Hoozemans, J. J. M., van der Vies, S. M., Rozemuller, A. J. M., van Horssen, J., & de Vries, H. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3895 · Cited by 293
Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy
Greenberg, S. M., Vonsattel, J.-P. G., Segal, A. Z., Chiu, R. I., Clatworthy, A. E., Liao, A., Hyman, B. T., & Rebeck, G. W. (1998) · Neurology · doi:10.1212/wnl.50.4.961 · Cited by 267 · cited 1×
“[59] and later supported by the finding that ε2 is associated with larger ICH-related haematoma volume and poorer functional outcome [60].”
ResultCerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts
Okamoto, Y., Yamamoto, T., Kalaria, R. N., Senzaki, H., Maki, T., Hase, Y., Kitamura, A., Washida, K., Yamada, M., Ito, H., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0925-9 · Cited by 249 · cited 1×
“BCAS approach in Tg-SwDI mice produced a 26% reduction of cerebral blood flow and a significant increase in leptomeningeal Aβ accumulation [112], whereas in APP23 mice BCAS was able to increase CAA in small cortical and leptomeningeal vessels [113].”
BackgroundHartz, A. M. S., Bauer, B., Soldner, E. L. B., Wolf, A., Boy, S., Backhaus, R., Mihaljevic, I., Bogdahn, U., Klünemann, H. H., Schuierer, G., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.627562 · Cited by 248
Chen, H.-K., Ji, Z.-S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.151084 · Cited by 209
Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone
Purro, S. A., Farrow, M. A., Linehan, J., Nazari, T., Thomas, D. X., Chen, Z., Mengel, D., Saito, T., Saido, T., Rudge, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0790-y · Cited by 191
Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy
Carrano, A., Hoozemans, J. J. M., van der Vies, S. M., van Horssen, J., de Vries, H. E., & Rozemuller, A. J. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000334916 · Cited by 186 · cited 2×
“The astrocytic release of cytokines in the presence of Aβ and the consequent initiation of the inflammatory process was proposed to lead to the BBB destabilization through an increased production of matrix-degrading enzymes such as MMP-2 and MMP-9 [16,17].”
BackgroundSadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154
Sex dimorphism profile of Alzheimer’s disease-type pathologies in an APP/PS1 mouse model
Jiao, S.-S., Bu, X.-L., Liu, Y.-H., Zhu, C., Wang, Q.-H., Shen, L.-L., Liu, C.-H., Wang, Y.-R., Yao, X.-Q., & Wang, Y.-J. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9589-x · Cited by 129 · cited 1×
“CAA development starts at 6 months of age and it is significantly more pronounced and severe—including microhaemorrhages and neuroinflammation—in female mice than in male ones [109].”
BackgroundHDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114 · cited 1×
“Specifically, it has been demonstrated that HDL reduces AD risk by decreasing vascular Aβ deposition and inflammation [80,81].”
BackgroundBrodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
Saito, S., Yamamoto, Y., Maki, T., Hattori, Y., Ito, H., Mizuno, K., Harada-Shiba, M., Kalaria, R. N., Fukushima, M., Takahashi, R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0429-5 · Cited by 110 · cited 1×
“Recent advances showed that taxifolin, a bioactive catechol-type flavonoid with antioxidant properties, inhibits Aβ aggregation in vitro and improves CBF, facilitating amyloid clearance in the brain and suppressing cognitive decline in a mouse model of CAA [127].”
BackgroundMonro, O. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00317-7 · Cited by 107
The effects of cerebral amyloid angiopathy on integrity of the blood-brain barrier
Magaki, S., Tang, Z., Tung, S., Williams, C. K., Lo, D., Yong, W. H., Khanlou, N., & Vinters, H. V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.004 · Cited by 93
Cerebral amyloid angiopathy as a cause of neurodegeneration
Smith, E. E. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14157 · Cited by 86 · cited 2×
“Moreover, alteration in vascular reactivity and in particular an impaired vasodilation have been identified early in the disease, before the onset of symptoms or the appearance of brain atrophy suggesting that they may be responsible of neurodegeneration [9].”
BackgroundMann, D. M. A., Davidson, Y. S., Robinson, A. C., Allen, N., Hashimoto, T., Richardson, A., Jones, M., Snowden, J. S., Pendleton, N., Potier, M.-C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1866-3 · Cited by 73 · cited 6×
“Since rodents generally do not develop CAA spontaneously, not even at very old ages, a variety of transgenic mouse models have been introduced that, similar to cerebral amyloidosis in humans, develop either Aβ-CAA only or both Aβ-CAA and parenchymal amyloid, or primarily parenchymal amyloid.”
BackgroundInfluentialApolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells
Sacre, S. M., Stannard, A. K., & Owen, J. S. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00261-8 · Cited by 73 · cited 1×
“Several lines of evidence previously suggested that high-density lipoprotein (HDL) has potent anti-thrombotic, anti-oxidant, anti-inflammatory and cytoprotective functions [76], all of which may affect AD.”
BackgroundBales, K. R., O’Neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., Wood, K. M., Volfson, D., Cirrito, J. R., Han, B.-H., et al. (2016) · Brain · doi:10.1093/brain/awv313 · Cited by 68 · cited 2×
“Although Ponezumab seemed to reduce Aβ deposition and to improve vessel function in transgenic mice [122], a phase 2 clinical trial showed that this drug neither improved vascular reactivity nor it influenced the number of microbleeds in humans [123].”
BackgroundPartial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid
Austin, S. A., & Katusic, Z. S. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18822474 · Cited by 52 · cited 1×
“processing of APP in both human cells and mouse cerebrovascular tissue [142] and of the angiotensin receptor blockers (i.”
BackgroundCarrano, A., Snkhchyan, H., Kooij, G., van der Pol, S., van Horssen, J., Veerhuis, R., Hoozemans, J., Rozemuller, A., & de Vries, H. E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.015 · Cited by 51
Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
Kamp, J. A., Moursel, L. G., Haan, J., Terwindt, G. M., Lesnik Oberstein, S. A. M. J., van Duinen, S. G., & van Roon-Mom, W. M. C. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0008 · Cited by 36 · cited 1×
“Age at first stroke is around 50 years and severe cognitive deterioration commonly develops in those who survive haemorrhagic lesions [46].”
BackgroundTau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy
You, Y., Perkins, A., Cisternas, P., Muñoz, B., Taylor, X., You, Y., Garringer, H. J., Oblak, A. L., Atwood, B. K., Vidal, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0680-z · Cited by 33
Cited by
The Glymphatic System: A Novel Component of Fundamental Neurobiology
Hablitz, L. M., & Nedergaard, M. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.0619-21.2021 · Cited by 453
Li, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
“Besides, RAGE peptide aptamers also can block RAGE signal transduction (Gatti et al. 2020).”
BackgroundMarazuela, P., Paez-Montserrat, B., Bonaterra-Pastra, A., Solé, M., & Hernández-Guillamon, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094972 · Cited by 31
Robert, J., Button, E. B., Martin, E. M., McAlary, L., Gidden, Z., Gilmour, M., Boyce, G., Caffrey, T. M., Agbay, A., Clark, A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00366-8 · Cited by 27
Metadata
- Authors
- Gatti, L., Tinelli, F., Scelzo, E., Arioli, F., Di Fede, G., Obici, L., Pantoni, L., Giaccone, G., Caroppo, P., Parati, E. A., & Bersano, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-13
- Volume
- 21
- Issue
- 10
- Pages
- 3435
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3025320105
- Cited by
- 90
- References
- 40
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.